fg--in my opinion, you have greatly underestimated the market for Hylenex for rehydration. Pediatric rehydration has always been a challenge. When the kids are dry (dehydrated) their veins are collapsed,and it is a noisy, screaming challenge to get the IV in place--frequently taking 2-3 attempts, sometimes up to 5-10 attempts--at which point the anguished parents either ask "is this necessary" or they just refuse further IV attempts. It is painful for the patient, painful for the parents to watch, and painful for the health care provider put in the position of starting the IV. At that point, all involved will be thrilled with the option of one needle stick with HYLENEX assisted fluid hydration. Once an initial amount of fluid is in, the patient is in a more hydrated state with veins that are no longer collapsed, and an IV if necessary at that time, would be much simpler. ER physicians and nurses will love this simpler mode of rehydration.
Family docs and pediatricians will find it so simple to use that they will use it in the office, rather than sending the patients to the ER for the historic IV,
ER docs will soon see the advantage of HYLENEX for
1--obese patients where it is difficult to start an IV
2--cancer patients whose veins have been destroyed.
3--drug abusers with no veins
4--hepatitis/HIV patients--avoiding a bloody needle stick
5--trauma patients--start multiple HYLENEX infusions in the field
6--combative patients when it is a challenge to get an IV in.
People used to think FAX machines, computers, and cell phones had no future.
It is a great product--be careful about selling it short
Idaho
Family docs and pediatricians will find it so simple to use that they will use it in the office, rather than sending the patients to the ER for the historic IV,
ER docs will soon see the advantage of HYLENEX for
1--obese patients where it is difficult to start an IV
2--cancer patients whose veins have been destroyed.
3--drug abusers with no veins
4--hepatitis/HIV patients--avoiding a bloody needle stick
5--trauma patients--start multiple HYLENEX infusions in the field
6--combative patients when it is a challenge to get an IV in.
People used to think FAX machines, computers, and cell phones had no future.
It is a great product--be careful about selling it short
Idaho
Recent HALO News
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 10:35:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/23/2026 08:16:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/23/2026 08:13:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/23/2026 08:11:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:32:00 PM
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer • PR Newswire (US) • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:18:04 PM
- U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma • PR Newswire (US) • 03/06/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:56:16 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:51:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:04:55 PM
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 02/17/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:21:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:20:59 AM
